Table 2. TEAEs of clinical relevance and... | American Society of Hematology

Table 2.

TEAEs of clinical relevance and special interest

TEAE	Luspatercept (N = 96)		Placebo (N = 49)		Crossover∗ (N = 38)
TEAE	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
TEAEs of clinical relevance
Hypertension†	21 (21.9)	3 (3.1)	1 (2.0)	0	7 (18.4)	0
Bone pain‡	42 (43.8)	3 (3.1)	3 (6.1)	0	8 (21.1)	0
TEAEs of special interest
TEE	2 (2.1)	1 (1.0)	0	0	2 (5.3)	1 (2.6)
EMH	10 (10.4)	0	2 (4.1)	1 (2.0)	2 (5.3)	0
Malignancies	0	0	2 (4.1)	2 (4.1)	0	0
Premalignant disorders	2 (2.1)	0	1 (2.0)	0	0	0

TEAE	Luspatercept (N = 96)		Placebo (N = 49)		Crossover∗ (N = 38)
TEAE	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
TEAEs of clinical relevance
Hypertension†	21 (21.9)	3 (3.1)	1 (2.0)	0	7 (18.4)	0
Bone pain‡	42 (43.8)	3 (3.1)	3 (6.1)	0	8 (21.1)	0
TEAEs of special interest
TEE	2 (2.1)	1 (1.0)	0	0	2 (5.3)	1 (2.6)
EMH	10 (10.4)	0	2 (4.1)	1 (2.0)	2 (5.3)	0
Malignancies	0	0	2 (4.1)	2 (4.1)	0	0
Premalignant disorders	2 (2.1)	0	1 (2.0)	0	0	0

Data are given as n (%).

Patients who crossed over from placebo to luspatercept.

Includes only the preferred term hypertension.

Includes only the preferred term bone pain.